Nucleus Network to Highlight Benefits of Conducting Early-Stage Clinical Trials in Australia During MassBio Event

11th October 2019

WHAT: Recently, a Frost & Sullivan report noted that Australia has become the preferred destination for early-stage clinical trials. On Monday 28th of October, Nucleus Network, Australia’s leading early-phase clinical research organization, will be presenting at MassBio to highlight the many benefits of ‘going down under’ including the lower cost of conducting trials in a high-quality, FDA-inspected facility; the 43.5 percent R&D cash rebate from the Australian government; and the ability to launch a Phase I trial without an IND, accelerating a company’s clinical program and moving their organization more quickly to critical value inflection points. Dr. Jason Lickliter, Chief Medical Officer of Nucleus Network, will lead a robust discussion that will provide details on preclinical requirements and strategies for moving faster to proof of concept and considerations for successful adaptive study design in Australia.

WHO: Dr. Jason Lickliter, Chief Medical Officer of Nucleus Network, and members of the Nucleus Network team. The event is free and open to MassBio members, non-members and the media.

WHEN: Monday, October 28th, 11:30 a.m. – 1:00 p.m.

WHERE: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA 02139